Epigenetic Drug Resets Fat Around Blood Vessels to Fight Heart Disease
A BET inhibitor called RVX-208 reprogrammed diseased perivascular fat, restoring blood vessel function in obese hypertensive patients.
Summary
Researchers at the University of Zurich discovered that a thin layer of fat wrapping small arteries plays a key role in cardiovascular disease. In healthy people this fat helps blood vessels relax, but in obesity and high blood pressure it flips to an inflammatory, vessel-damaging state. The team treated human artery samples from obese hypertensive patients with RVX-208, a drug that blocks BET proteins — epigenetic regulators that amplify disease-driven gene activity. The drug restored the vessels' ability to relax, reduced inflammation and oxidative stress, and converted the diseased fat back to a healthy state. Mouse studies confirmed these benefits. The key downstream target appeared to be HK2, an enzyme involved in sugar metabolism, specifically within the perivascular fat.
Detailed Summary
Cardiovascular disease remains a leading cause of death worldwide, and a key early step is endothelial dysfunction — the inability of blood vessels to dilate properly. Researchers from the University of Zurich have now identified a promising new target: the thin fat layer wrapped around small arteries, called perivascular adipose tissue or PVAT, and an epigenetic drug that can reset its diseased state.
In obese, hypertensive patients, PVAT stops sending relaxation signals to vessels and instead releases inflammatory molecules including IL-1β, IL-6, and TNF-α. This drives oxidative stress, depletes nitric oxide, and structurally remodels the artery wall. The researchers confirmed this by studying small arteries taken from fat biopsies of 27 obese hypertensive patients versus lean healthy controls, finding clear functional and molecular impairment in patient vessels.
The team then applied RVX-208, a BET inhibitor that broadly suppresses stress-driven gene programs rather than blocking a single inflammatory molecule. It outperformed individual anti-cytokine antibodies, restoring vessel relaxation, cutting reactive oxygen species, and normalizing inflammatory gene expression. Crucially, its benefits were roughly doubled when the perivascular fat remained intact, and it converted diseased PVAT back to a health-promoting state — pinpointing the fat, not the vessel wall, as the primary site of action.
Mouse experiments corroborated the human findings, reducing arterial stiffness, rescuing endothelial function, and correcting mitochondrial dysfunction in PVAT. Among 84 cardiometabolic genes analyzed, the enzyme HK2 — a glycolysis regulator — emerged as the most significantly downregulated target, and its change was confined to PVAT, suggesting a metabolic reprogramming mechanism.
While these findings are compelling, RVX-208 has not yet demonstrated clinical efficacy in large cardiovascular trials. The human data are from ex vivo tissue experiments, and translation to living patients requires further study. Still, this work opens a novel therapeutic angle: targeting the fat-vessel interface epigenetically to address the root cause of cardiometabolic vascular damage.
Key Findings
- RVX-208, a BET inhibitor, restored blood vessel relaxation in arteries from obese hypertensive patients by reprogramming perivascular fat.
- Perivascular fat switches from vessel-protective to vessel-damaging in obesity and hypertension, driving inflammation and oxidative stress.
- The drug's benefit was doubled when perivascular fat remained intact, confirming fat as the primary disease driver rather than the vessel wall.
- HK2, a glycolysis enzyme, was the top downregulated gene in diseased perivascular fat after treatment, suggesting a metabolic mechanism.
- Mouse models confirmed RVX-208 reduces arterial stiffness, restores endothelial function, and corrects mitochondrial dysfunction in fat tissue.
Methodology
This is a research summary reporting on a peer-reviewed study published in Cell Reports from the University of Zurich. Evidence includes ex vivo human artery experiments from 27 obese hypertensive patients, paired PVAT-intact versus PVAT-removed vessel comparisons, and in vivo mouse cardiometabolic disease models. Source credibility is high; Lifespan.io is a reputable longevity science outlet.
Study Limitations
Human data are entirely ex vivo — arteries were studied outside the body — so in vivo patient efficacy is unconfirmed. RVX-208 has had mixed results in prior cardiovascular trials and has not yet cleared phase III endpoints. The article content was truncated, so downstream mechanistic findings around HK2 may be incompletely represented here.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.